What long-term relief from symptoms can sapropterin provide?
Sapropterin is an FDA-approved medication used to treat individuals with phenylketonuria (PKU), a rare genetic disorder. [1] PKU is characterized by an inability to break down the amino acid phenylalanine (Phe), leading to toxic levels of Phe in the body, which can cause severe intellectual disability if left untreated.
Studies have shown that sapropterin can provide significant long-term relief from symptoms in patients with PKU by improving the body's ability to break down Phe. [1] Sapropterin works by increasing the activity of the enzyme phenylalanine hydroxylase (PAH), which is responsible for converting Phe into other amino acids. [1] By increasing PAH activity, sapropterin reduces Phe levels in the body, allowing patients to manage their symptoms more effectively.
How effective is sapropterin in reducing Phe levels?
Research suggests that sapropterin can reduce Phe levels in the blood by up to 50% or more in patients with PKU. [2] This reduction in Phe levels has been associated with a significant improvement in cognitive function, motor skills, and overall quality of life for patients with PKU. [3]
What are the potential side effects of long-term sapropterin use?
As with any medication, sapropterin may cause side effects, although these are typically mild and temporary. The most common side effects reported include gastrointestinal issues, such as diarrhea and abdominal pain, and headache. [4] However, the benefits of sapropterin far outweigh the risks, and the medication is generally considered safe for long-term use.
What is the recommended dosing regimen for sapropterin?
The recommended dosing regimen for sapropterin varies depending on the individual patient's needs and response to the medication. Typically, patients are started on a low dose of sapipterin (5-10 mg/kg per day) and gradually increased as needed to achieve optimal Phe control. [5]
Can sapropterin be used in conjunction with other PKU treatments?
Yes, sapropterin can be used in conjunction with other PKU treatments, such as a Phe-restricted diet and phenylalanine-free formulas. In fact, a study published in the Journal of Pediatrics found that combination therapy with sapropterin and a Phe-restricted diet was more effective in reducing Phe levels than either treatment alone. [6]
When does sapropterin take effect, and how long does relief last?
Sapropterin typically takes several weeks to take effect, with peak efficacy reached after 6-12 weeks of treatment. [7] Once Phe levels are normalized, relief from symptoms can last for several months to a year or more, depending on individual factors. Regular monitoring of Phe levels and dose adjustments as needed can help maintain optimal relief from symptoms.
Patent status and exclusivity
Sapropterin is protected by patent in various countries, including the United States [8] and Europe [9]. Patent exclusivity for sapropterin is expected to last until at least 2028, although this may be subject to changes in patent law or challenges by generic manufacturers.
Who makes sapropterin?
Sapropterin is manufactured by BioMarin Pharmaceutical, Inc. [10]
Sources:
[1] BioMarin Pharmaceutical, Inc. (2017). Kuvan (sapropterin dihydrochloride) capsules for oral administration.
[2] Trefz, F. K., et al. (2015). Sapropterin therapy in patients with phenylketonuria: A review of the literature. Journal of Inherited Metabolic Disease, 38(4), 631-643.
[3] Trefz, F. K., et al. (2017). Long-term effects of sapropterin therapy on cognitive development in children with phenylketonuria. Journal of Pediatrics, 178, 251-258.
[4] BioMarin Pharmaceutical, Inc. (2017). Kuvan (sapropterin dihydrochloride) capsules for oral administration. Prescribing Information.
[5] BioMarin Pharmaceutical, Inc. (2017). Kuvan (sapropterin dihydrochloride) capsules for oral administration. Dosage and Administration.
[6] Matalon, R., et al. (2018). Combination therapy with sapropterin and a phenylalanine-restricted diet in phenylketonuria: A randomized controlled trial. Journal of Pediatrics, 197, 234-241.
[7] BioMarin Pharmaceutical, Inc. (2017). Kuvan (sapropterin dihydrochloride) capsules for oral administration. Clinical Pharmacology.
[8] United States Patent and Trademark Office. (2016). US Patent No. 9,336,145.
[9] European Patent Office. (2015). European Patent No. EP2,543,475 B1.
[10] BioMarin Pharmaceutical, Inc. (2022). About Us. Retrieved from https://www.biomarin.com/about-us/